ProAct Study: New Features of Insulin Pumps Improve Diabetes Management and Glycemic Control in Patients after Transition of Continuous Subcutaneous Insulin Infusion Systems
- 1 September 2013
- journal article
- research article
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 15 (9) , 738-743
Abstract
Background: Continuous subcutaneous insulin infusion (CSII) patients experience switches of pump systems on a regular basis. We investigated the impact of transition from older pumps to the Accu-Chek ® Combo system (Roche Diagnostics Deutschland GmbH, Mannheim, Germany) on a patient's glycemic control and diabetes management. Patients and Methods: In total, 299 patients (172 female, 127 male; mean±SD age, 39.4±15.2 years; CSII duration, 7.0±5.2 years) were enrolled by 61 European sites into this uncontrolled prospective trial. Glycemic control, safety, and diabetes management parameters were measured at baseline and after 3 and 6 months. Changes from baseline were analyzed. Results: After transition to the new insulin pump, mean±SD hemoglobin A1c (HbA1c) values decreased from 7.8±1.1% (baseline) to 7.7±1.1% (end point). The proportion of patients with HbA1c 8.0% decreased (baseline, 36.2%; end point, 32.7%; P P n =48) had a larger HbA1c decrease (–0.40%) than long-term (≥3 years) users ( n =251) (–0.07%; P P P <0.05) during the study. Conclusions: Transition from older pump systems to the Accu-Chek Combo system in a large patient population resulted in stable glycemic control with significant improvements in HbA1c in patients with unsatisfactory baseline HbA1c and shorter pump use. Increased frequency of self-monitoring of blood glucose and decrease of bolus frequency could suggest a more confident diabetes management and a reduced need for correction boluses.Keywords
This publication has 21 references indexed in Scilit:
- Robust Fault Detection System for Insulin Pump Therapy Using Continuous Glucose MonitoringJournal of Diabetes Science and Technology, 2012
- Bolus calculator improves long-term metabolic control and reduces glucose variability in pump-treated patients with Type 1 diabetesNutrition, Metabolism and Cardiovascular Diseases, 2012
- Insulin-Pump Therapy for Type 1 Diabetes MellitusNew England Journal of Medicine, 2012
- A Review of the Security of Insulin Pump Infusion SystemsJournal of Diabetes Science and Technology, 2011
- Insulin pump therapy in adultsDiabetes Research and Clinical Practice, 2011
- Clinical Performance of Three Bolus Calculators in Subjects with Type 1 Diabetes Mellitus: A Head-to-Head-to-Head ComparisonDiabetes Technology & Therapeutics, 2010
- Pilot Study for Assessment of Optimal Frequency for Changing Catheters in Insulin Pump Therapy—Trouble Starts on Day 3Journal of Diabetes Science and Technology, 2010
- Evolution of Diabetes Insulin Delivery DevicesJournal of Diabetes Science and Technology, 2010
- Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH‐based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5‐nations trialDiabetic Medicine, 2005
- Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes.Diabetes Care, 1999